Brought to you by 
Gossamer Bio closes $230mm Series B round
23 Jul 2018
Executive Summary
Gossamer Bio Inc. raised $230mm through its Series B round led by Hillhouse Capital. New buyers Invus, a subsidiary of the Abu Dhabi Investment Authority, the Baupost Group, and Polaris Partners were joined by returning backers Arch Venture Partners and Omega Funds. Gossamer is developing treatments for autoimmune, GI, allergy/inflammation, and immuno-oncology indications and will use the funds to advance its candidates through early- and mid-stage trials.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gossamer Bio closes $230mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice